

# **New Trends in Antibiotics: Research and Therapy**

**G. Gialdroni Grassi and L. D. Sabath**  
**Editors**

# NEW TRENDS IN ANTIBIOTICS: RESEARCH AND THERAPY

---


Proceedings of the International Symposium on New Trends in Antibiotics:  
Research and Therapy held in Milan, Italy, October 29-31, 1980.

*Editors:*

G. Gialdroni Grassi

*and*

L.D. Sabath



1981

ELSEVIER/NORTH-HOLLAND BIOMEDICAL PRESS  
AMSTERDAM · NEW YORK · OXFORD

© 1981 Elsevier/North-Holland Biomedical Press

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner.

ISBN for this volume: 0-444-80326-2

ISBN for the series: 0-444-80040-9

Published by:

Elsevier/North-Holland Biomedical Press

335 Jan van Galenstraat, P.O. Box 211

Amsterdam, The Netherlands

Sole distributors for the USA and Canada:

Elsevier North Holland Inc.

52 Vanderbilt Avenue

New York, N.Y. 10017

#### Library of Congress Cataloging in Publication Data

International Symposium on New Trends in Antibiotics:

Research and Therapy (1980 : Milan, Italy)

New trends in antibiotics--research and therapy.

(Symposia of the Giovanni Lorenzini Foundation ;  
v. 10)

Bibliography: p.

Includes index.

1. Antibiotics--Congresses. I. Gialdroni Grassi, G.  
(Giuliana) II. Sabath, L. D. III. Title. IV. Series.

[DNLM: 1. Antibiotics--Congresses. W3 SY1056 v.10 1980 /  
QV 350 I607n 1980]

RM265.2.I58 1980 615'.329

81-4639

ISBN 0-444-80326-2 (U.S.)

AACR2

## PREFACE

The lectures and the papers that are collected in this volume were presented at the Symposium on "NEW TRENDS IN ANTIBIOTICS: Research and Therapy", held in Milano (Italy), on October 29-31, 1980.

The Symposium, sponsored also by the Italian Society of Chemotherapy and the Italian Society of Hospital Pharmacists, was organized by Fondazione Lorenzini to celebrate the 10<sup>th</sup> anniversary of its foundation, a decade in which its initiatives have contributed a great deal to the scientific progress in many fields of biological and medical sciences.

The subject chosen for this Symposium was quite ambitious: it intended to cover the present status and to indicate the future development of antibacterial chemotherapy. But this task did not seem to be too hard for the specialists who convened here from all over the world. Their reports show how the present knowledges and experiences are open to new perspectives for the future : a sign of the vitality of this branch of science.

Giuliana Gialdroni Grassi

# CONTENTS

## Preface

## TETRACYCLINES

### Tetracyclines: Chemical aspects and some structure-activity relationships

U. Valcavi

### The tetracyclines: Microbial sensitivity and resistance

S.B. Levy

### Medical uses of tetracyclines

J. Jeljaszewicz

## AMINOGLYCOSIDE ANTIBIOTICS

### Aminoglycoside antibiotics: Chemical aspects and future trends

K.E. Price

### Aminoglycoside antibiotics: General aspects and resistance

J.E. Davies and S.A. Kagan

### Evolutionary relationships between plasmid-mediated aminoglycoside-modifying enzymes from gram-positive and gram-negative bacteria

P. Courvalin, C. Carlier and E. Collatz

## $\beta$ -LACTAM ANTIBIOTICS: PENICILLIN AND CEPHALOSPORINS

### $\beta$ -lactamases and the new $\beta$ -lactams

M.H. Richmond

### $\beta$ -lactam antibiotics: Areas of use in the 1980's

H.C. Neu

### $\beta$ -lactamase inhibition by clavulanic acid and other inhibitors with $\beta$ -lactam structure. Theoretical aspects and clinical applications

R. Münch, R. Lüthy and W. Siegenthaler

## REVIEWS

### Prospects for research in the field of antibacterial chemotherapy

P. Sensi

### Development of bacterial resistance to antibiotics

B. Wiedemann

### Combined activity of antibiotics

G. Gialdroni Grassi



## ANTIBIOTICS AND SOCIETY

## The use of antibiotics in the developing world

C. Wen-Chieh

223

## Some medical, social and scientific advances resulting from the use of antibiotics

L.D. Sabath and D. Brooker

229

## Strategy of in-hospital use of antiinfective agents

G.A. Malacrida, G. Avondoglio, A. Bernardini, N. Martini,  
L. Castellani, A. Piccolboni, L. Giuliani and G. Ostino

235

## Socioeconomic and behavioral residua of antibiotic therapy in infancy and childhood

J.D. Nelson and E.A. Mohs

247

## CONTRIBUTED PAPERS

*Tetracyclines*

## Doxycycline activity in human bile

M. Taufer, J. Zangger and M. Resch

257

## One-dose Doxycycline therapy in conorii rickettsiosis

C. D'Amato, R. Giannuzzi, F. Spinazzola and G. Visco

260

*Aminoglycoside Antibiotics*

## Microbiological evaluation of aminoglycosides: Procedural aspects, comparative activity and perspectives for therapeutical use

G.F. Abbate, I. Alagia, L. D'Aprèa, V. Leonessa,  
A.P. Pilloni and P. Altucci

263

## Pharmacokinetics and toxicity of Amikacin in the neonate

B.M. Assael, P. Capodaglio, G. Cavanna, R. Parini,  
F. Rusconi and A. Viganò

266

Diversity of R-plasmids in epidemic *Serratia marcescens* from the south west of England

J.L. Bidwell, D.S. Reeves and D.W. Bullock

268

## Aminoglycoside antibiotics: Structure-toxicity relationship

A.L.C.M. Lima, R.F. Marseillan and A.P. Corrado

274

## Study of the therapeutic effects and of ototoxicity tolerance of Ribostamycin in the postoperative treatment with antibiotics

P. Frasson, M. Rossi, G. Zaninotto and S. Narne

277

## Penetration and levels of Tobramycin in human lung tissue

N. Martini, G. Scroccaro, A.B. Salmasso, A. Piccolboni  
and V. Puchetti

280

Exploratory studies directed towards the total chemical synthesis of aminoglycosides	
B. Quiclet-Sire, D. Semeria, A.M. Sepulchre and S.D. Gero	283
<i>In vitro</i> activity of Sisomicin compared to that of other aminoglycosides	
D.S. Reeves, M.J. Bywater and H.A. Holt	286
Ribostamycin "in vitro" cytotoxicity	
A. Vespasiani, P. Reda, F. Cicogna and G.A. Robecchi	289
$\beta$ -Lactam Antibiotics: Penicillin and Cephalosporins	
New $\beta$ -lactam antibiotics for treatment of <i>Pseudomonas aeruginosa</i> infections	
A. Bauernfeind	292
"New" penicillin-binding proteins (PBPs) in <i>E. coli</i> and location in the inner membrane of functionally major PBPs	
G.A. Botta, L.S. Schmidt and J.T. Park	295
Response to cell division inhibition by several $\beta$ -lactam antibiotics in different penicillin-binding proteins (PBPs) deficient mutants of <i>E. coli</i>	
G.A. Botta, L. Schmidt, M.C. Grignolo, A. Costa and J.T. Park	298
Pharmacokinetics of Cefotaxime in subjects with chronic bronchitis	
P.C. Braga, F. Scaglione, G. Scarpazza, C. Cedrini and F. Frascini	301
Concentrations of three $\beta$ -lactam-antibiotics in human brain abscess fluids and of Cefotaxime in CSF of patients with inflamed and uninflamed meninges	
O. Brückner, H. Collmann and H. Hoffmann	304
<i>Streptococcus faecalis</i> resistance to penicillin is accompanied by the increase of a penicillin binding protein	
R. Fontana, R. Cerini and G.A. Meloni	307
Clinical experience with Cefotaxime in 35 cases of severe infections	
G. Ippolito, A. Sirianni, C. Struglia, F. Zechini and G. Visco	310
Our experience with Mezlocillin in the therapy of life-threatening infections	
F. Paradisi, R. Cioffi, P. Cristiano, M.R. Iovene, F. Simioli and R.A. Salerno	313
Cefotaxime in the therapy of serious infections	
F. Paradisi, P. Cristiano, R. Cioffi, M.R. Iovene, B. Amantea and P. Russo	316

Cefoperazone in urinary-tract-infections. Tests - problems - results	319
J. Zangger, M. Taufer and K. Kratochvil	
Reviews	
Infectious endocarditis: Our more recent experience	322
P. Altucci, G.F. Abbate, I. Alagia and V. Leonessa	
Transferable trimethoprim resistance amongst hospital isolates	325
S.G.B. Amyes, C.J. McMillan and J.L. Drysdale	
A comparison of a radioenzyme method with HPLC and bioassay for the measurement of chloramphenicol in serum	328
R. Wise, K.A. Bedford and P.J. Wills	
Influence of various antibiotics on mitogen induced proliferative responses of human lymphocytes	331
C. De Simone, D. Meli, A. Campanelli, F. Fanari and F. Sorice	
Influence of various antibiotics on polymorphonuclear chemotaxis. "In vivo" and "in vitro" studies	333
C. De Simone, D. Meli, D. Ricca, C. Capozzi and F. Sorice	
A model of interaction between antibiotics and immunity	336
R. Licordari, A.M. Cardini, G. Ippolito and G. Macri	
The Strategy of Antibiotic Controls in Hospitals	
On the use of chemoantibiotics - Analysis of some data from seven hospitals in Rome	339
A. Colicchia, M. Ciampini and G. Ceccarelli	
Consequences of a changed antibiotic strategy in an urologic department - A six year follow-up	343
C.P. Schmidbauer and P. Porpáczy	
Research and practical considerations on the use of some antibiotics in hospitals	347
R. Rondanelli, R. Guaglio, M. Comelli and L. Rocchi	
Author index	353



# TETRACYCLINES

TETRA-CYCLES

## TETRACYCLINES: CHEMICAL ASPECTS AND SOME STRUCTURE-ACTIVITY RELATIONSHIPS

UMBERTO VALCAVI

Cattedra di Chimica Organica Applicata, Università di Milano, via Saldini, 50, Milano (Italy)

### INTRODUCTION

Tetracyclines are one of the oldest family of antibiotics (in fact, they appeared in the late 40's), nevertheless they are still widely used. This long and good life of tetracyclines is the result of the characteristics of these antibiotics: broad antimicrobial spectrum, low toxicity, few allergic reactions (only low incidence of phototoxicity), good oral absorption, low cost. The major drawbacks of tetracyclines are the deposition in calcified tissues with stains and impairments of bone and teeth (therefore, tetracyclines are not recommended in pregnancy and in children younger than 12 years) and sometimes development of resistance.

From 1950 so far a great deal of work was performed in the field of tetracyclines: their structure was cleared in 1953-1954 (by the combined effort of R.B. Woodward group and Pfizer Research Laboratories), stereochemistry was elucidated in 1963 through X-ray crystallography, absolute configuration was confirmed, total synthesis of various tetracyclines (even though not economical) was performed, biosynthesis has been very carefully elucidated, mechanism of action is now clear, about one thousand derivatives of tetracyclines have been prepared (of these about 20 by fermentation processes).

In conclusion, few classes of drugs have been so deeply and thoroughly studied as the tetracycline family.

Seven tetracyclines are to-day clinically used (see table 1).

This table shows that there are two generations of tetracyclines: the first-generation tetracyclines (from 1948 to 1957) are produced by fermentation, whereas the second-generation tetracyclines (from 1965 to 1972) are produced by semi-synthesis.

Tetracycline itself remains the most used member of the family, whereas doxycycline (which induces sustained blood levels) is the first "one-day" tetracycline. Some of the most interesting properties of tetracyclines clinically used to-day are shown in table 2.

TABLE 1

			Product	Year of discovery	Produced by
Cl		H	Chlorotetracycline	1948	<u>Streptomyces aureofaciens</u>
H		H	Oxytetracycline	1948	<u>Streptomyces rimosus</u>
H		H	Tetracycline	1953	Chemically from chlorotetracycline or <u>Streptomyces aureofaciens</u>
Cl		H	Demethylchlorotetracycline	1957	Mutant of <u>Streptomyces aureofaciens</u>
H		H	Methacycline	1965	chemically
H		H	Doxycycline	1967	chemically
		H	Minocycline	1972	chemically




TABLE 2


Product	In vitro relative potency against <u>S. aureus</u>	ED50 oral in infected mice <u>S. aureus</u> mg/kg	Recommended daily-dose mg/day	% of oral absorption	half-life hrs	protein binding %
Tetracycline	100	5.8	500	77-80%	8.2	55-64%
Chlorotetracycline	130-200	7.6	500	25-30%	5.6	43-55%
Oxytetracycline	80	7.2	500	58%	9.2	20-35%
Demethylchlorotetracycline	150	6.0	300	66%	12	75-91%
Methacycline	150	4.5	300	88%	14	78%
Doxycycline	110	2.6	150	95%	17	82-93%
Minocycline	200	3.5	150	95%	16	76%



# CHEMICAL TRANSFORMATION OF TETRACYCLINES FAMILY

Many chemical changes were performed on tetracyclines. In figure 1 the numbers and arrows denote the centers for which relevant derivatives are available.

Fig. 1



Till now no changes are performed at carbons 3, 4 a, 8 and 10 (without altering the whole structure of the molecule).

In the following reports we describe only the most relevant modifications, and (for simplification) only "active" or "non-active" (but the accurate data of activity may be found in the pertinent literature).

Some derivatives were obtained from tetracycline, others from doxycycline, others from 6-deoxy-6-demethyltetracycline and few from minocycline.


## a) Chemistry in position 2

The most interesting derivatives of carbon 2 are shown in figure 2: the last product (2-acetyl-2-decarboxamido-tetracycline) was obtained by fermentation, all the others by chemical reactions.

All the products are inactive or less active than the parent antibiotics (only rolitetracycline is active because in water it reverts into the parent tetracycline).

In conclusion, carboxamide group is very important for bioactivity and no important changes are possible in position 2.

Fig. 2



#### b) Chemistry in position 4

Some of the most important derivatives in position 4 are shown in figure 3

No useful changes were performed in position 4: the orientation of dimethylamino group below the plane of ring A is essential for bioactivity' (4-epitetetracycline has a weak activity in-vitro and none in-vivo), also the basicity of dimethylamino group (with pKa 9.3) is important because more or less substituted amino-groups are less active; steric phenomena are also important because derivatives with higher dialkylamino groups have a lower bioactivity.

#### c) Chemistry in position 5

Some of the most interesting derivatives in position 5 are shown in figure 4. Position 5 appears to be not very critical for bioactivity.

It is interesting to note that, whereas 5,5a-didehydro compound is inactive, 5,5a-didehydro-6-epioxytetracycline is surprisingly highly active both in-vitro and in-vivo.

Fig. 3






Fig. 4



#### d) Chemistry in position 5a

Some of the most interesting derivatives in position 5a are shown in figure 5.


Fig. 5



A blocked mutant of *S. aureofaciens* produces 5a(11a)-dehydro-chlorotetracycline and from this product the other derivatives have been obtained by chemical steps, as depicted in figure 6.

It seems that the 5a-position is not very critical for antibiotic activity, but natural tetracyclines are still the best compounds and no improvements were obtained so far with modifications in position 5a.

Fig. 6





### e) Chemistry in position 6

Some 6-epi compounds have been described above.

Position 6 is not critical for antibiotic activity and some of the most interesting, and clinically used tetracyclines have been obtained through changes in position 6: in fact 6-demethylchlorotetracycline, methacycline, doxycycline, are products modified in position 6.

Some of the most interesting chemical reactions in position 6 are shown in figures 7 and 8.

Fig. 7





Fig. 8

